X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs GLENMARK PHARMA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD GLENMARK PHARMA STRIDES SHASUN LTD/
GLENMARK PHARMA
 
P/E (TTM) x 13.2 12.2 107.8% View Chart
P/BV x 1.5 3.2 47.3% View Chart
Dividend Yield % 0.6 0.4 173.3%  

Financials

 STRIDES SHASUN LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
GLENMARK PHARMA
Mar-17
STRIDES SHASUN LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,275993 128.4%   
Low Rs918729 125.9%   
Sales per share (Unadj.) Rs389.6325.5 119.7%  
Earnings per share (Unadj.) Rs28.039.3 71.2%  
Cash flow per share (Unadj.) Rs48.948.7 100.5%  
Dividends per share (Unadj.) Rs4.502.00 225.0%  
Dividend yield (eoy) %0.40.2 176.7%  
Book value per share (Unadj.) Rs303.1159.2 190.4%  
Shares outstanding (eoy) m89.42282.17 31.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.82.6 106.4%   
Avg P/E ratio x39.221.9 178.9%  
P/CF ratio (eoy) x22.417.7 126.7%  
Price / Book Value ratio x3.65.4 66.9%  
Dividend payout %16.15.1 316.1%   
Avg Mkt Cap Rs m98,036242,991 40.3%   
No. of employees `0005.813.0 44.7%   
Total wages/salary Rs m5,88116,408 35.8%   
Avg. sales/employee Rs Th6,005.97,083.9 84.8%   
Avg. wages/employee Rs Th1,014.01,265.4 80.1%   
Avg. net profit/employee Rs Th431.2855.1 50.4%   
INCOME DATA
Net Sales Rs m34,83491,857 37.9%  
Other income Rs m1,686374 451.2%   
Total revenues Rs m36,52092,230 39.6%   
Gross profit Rs m6,42820,367 31.6%  
Depreciation Rs m1,8722,644 70.8%   
Interest Rs m2,2692,373 95.6%   
Profit before tax Rs m3,97315,724 25.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,006-810 124.2%   
Tax Rs m4703,827 12.3%   
Profit after tax Rs m2,50111,088 22.6%  
Gross profit margin %18.522.2 83.2%  
Effective tax rate %11.824.3 48.6%   
Net profit margin %7.212.1 59.5%  
BALANCE SHEET DATA
Current assets Rs m38,16568,746 55.5%   
Current liabilities Rs m30,40227,027 112.5%   
Net working cap to sales %22.345.4 49.1%  
Current ratio x1.32.5 49.4%  
Inventory Days Days7785 91.0%  
Debtors Days Days10496 109.4%  
Net fixed assets Rs m37,63924,132 156.0%   
Share capital Rs m894282 316.9%   
"Free" reserves Rs m26,21044,643 58.7%   
Net worth Rs m27,10544,925 60.3%   
Long term debt Rs m16,37745,363 36.1%   
Total assets Rs m81,168117,639 69.0%  
Interest coverage x2.87.6 36.1%   
Debt to equity ratio x0.61.0 59.8%  
Sales to assets ratio x0.40.8 55.0%   
Return on assets %5.911.4 51.4%  
Return on equity %9.224.7 37.4%  
Return on capital %12.119.1 62.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46556,152 24.0%   
Fx outflow Rs m4,0768,084 50.4%   
Net fx Rs m9,38948,068 19.5%   
CASH FLOW
From Operations Rs m2,8816,574 43.8%  
From Investments Rs m-7,051-7,124 99.0%  
From Financial Activity Rs m3,3825,432 62.3%  
Net Cashflow Rs m-7881,992 -39.5%  

Share Holding

Indian Promoters % 27.7 48.3 57.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 6.9 547.8%  
FIIs % 8.6 34.4 25.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.5 246.7%  
Shareholders   56,241 56,727 99.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  FULFORD INDIA  SHASUN PHARMA  

Compare STRIDES SHASUN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS